Table 3.

Meta-Analysis of the Association Between the PPARγ Pro12Ala Polymorphism and NAFLD, RA, and PsA

				Test of association			Test of heterogeneity
Polymorphism	Population	Disease	No. of studies	OR	95% CI	p-value	Model	p-value	I2
Ala vs. Pro allele	Overall	NAFLD	5	0.936	0.672–1.302	0.693	R	0.074	53.1
	European	NAFLD	2	1.128	0.863–1.475	0.378	F	0.380	0
	East Asian	NAFLD	3	0.700	0.496–0.987	0.042	F	0.206	36.7
	East Asian	RA	2	0.467	0.188–1.161	0.101	R	0.060	71.7
	European	PsA	2	0.869	0.465–1.627	0.662	R	0.004	88.1
Ala/Ala+Ala/Pro vs. Pro/Pro (Dominant)	Overall	NAFLD	5	0.882	0.703–1.105	0.275	F	0.110	46.9
	European	NAFLD	2	1.051	0.782–1.413	0.742	F	0.337	0
	East Asian	NAFLD	3	0.688	0.484–0.978	0.037	F	0.186	40.4
	East Asian	RA	2	0.465	0.176–1.230	0.323	R	0.048	74.3
	European	PsA	2	0.895	0.484–1.654	0.723	R	0.009	85.2
Ala/Ala+Pro/Pro vs. Ala/Pro (Overdominant)	Overall	NAFLD	5	1.210	0.960–1.525	0.107	F	0.178	36.4
	European	NAFLD	2	1.051	0.773–1.430	0.750	F	0.297	7.96
	East Asian	NAFLD	3	1.453	1.023–2.065	0.037	F	0.186	40.4
	East Asian	RA	2	2.109	0.766–5.808	0.149	R	0.040	76.2
	European	PsA	2	1.050	0.639–1.724	0.848	R	0.039	76.4

OR, odds ratio; CI, confidence interval; F, fixed-effects model; R, random-effects model.